| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 38 | 2025 | 550 | 10.270 |
Why?
|
| Latent Tuberculosis | 11 | 2022 | 75 | 4.580 |
Why?
|
| Antitubercular Agents | 21 | 2025 | 275 | 4.360 |
Why?
|
| Mycobacterium tuberculosis | 13 | 2023 | 430 | 3.710 |
Why?
|
| Bacterial Infections | 15 | 2025 | 327 | 3.640 |
Why?
|
| Emergency Service, Hospital | 40 | 2026 | 1224 | 3.600 |
Why?
|
| Interferon-gamma Release Tests | 12 | 2022 | 91 | 3.180 |
Why?
|
| Meningitis, Bacterial | 14 | 2023 | 98 | 3.130 |
Why?
|
| Urinary Tract Infections | 13 | 2022 | 342 | 3.070 |
Why?
|
| Bacteremia | 15 | 2023 | 446 | 2.780 |
Why?
|
| Child | 132 | 2026 | 26341 | 2.650 |
Why?
|
| Herpes Simplex | 8 | 2025 | 59 | 2.580 |
Why?
|
| Infant | 96 | 2025 | 13352 | 2.400 |
Why?
|
| Tuberculin Test | 13 | 2022 | 120 | 2.370 |
Why?
|
| Rifampin | 6 | 2025 | 128 | 2.290 |
Why?
|
| Hypothermia | 5 | 2025 | 62 | 2.210 |
Why?
|
| Fever | 18 | 2024 | 312 | 2.140 |
Why?
|
| Isoniazid | 6 | 2025 | 69 | 2.130 |
Why?
|
| Pediatrics | 12 | 2023 | 1252 | 1.880 |
Why?
|
| Adolescent | 84 | 2026 | 20987 | 1.860 |
Why?
|
| Humans | 204 | 2026 | 131163 | 1.830 |
Why?
|
| Child, Preschool | 70 | 2025 | 15110 | 1.810 |
Why?
|
| Appendicitis | 6 | 2023 | 132 | 1.680 |
Why?
|
| Retrospective Studies | 70 | 2025 | 17753 | 1.620 |
Why?
|
| Influenza, Human | 9 | 2019 | 712 | 1.620 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 7 | 2023 | 86 | 1.520 |
Why?
|
| Simplexvirus | 4 | 2022 | 100 | 1.520 |
Why?
|
| Sepsis | 9 | 2023 | 493 | 1.490 |
Why?
|
| Infant, Newborn | 50 | 2025 | 8635 | 1.470 |
Why?
|
| Meningitis | 3 | 2021 | 96 | 1.330 |
Why?
|
| Male | 101 | 2026 | 64957 | 1.300 |
Why?
|
| Female | 105 | 2026 | 70963 | 1.280 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 5 | 2012 | 196 | 1.240 |
Why?
|
| Coinfection | 4 | 2023 | 187 | 1.230 |
Why?
|
| Texas | 24 | 2024 | 3686 | 1.210 |
Why?
|
| Shock, Septic | 5 | 2023 | 150 | 1.120 |
Why?
|
| Ultrasonography | 6 | 2020 | 943 | 1.120 |
Why?
|
| Emergency Medical Services | 6 | 2021 | 352 | 1.100 |
Why?
|
| Pediatric Emergency Medicine | 3 | 2024 | 44 | 1.100 |
Why?
|
| Tuberculosis, Pleural | 2 | 2022 | 9 | 1.060 |
Why?
|
| Acute Kidney Injury | 4 | 2021 | 705 | 1.040 |
Why?
|
| Osteomyelitis | 4 | 2025 | 209 | 1.030 |
Why?
|
| Cross-Sectional Studies | 25 | 2024 | 3829 | 1.020 |
Why?
|
| Tuberculosis, Pulmonary | 5 | 2019 | 238 | 1.020 |
Why?
|
| Cerebrospinal Fluid Proteins | 3 | 2018 | 24 | 1.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2020 | 919 | 1.010 |
Why?
|
| Antibiotics, Antitubercular | 3 | 2016 | 38 | 1.010 |
Why?
|
| Sensitivity and Specificity | 18 | 2025 | 2085 | 1.000 |
Why?
|
| Pneumonia | 3 | 2025 | 341 | 0.980 |
Why?
|
| Transplant Recipients | 3 | 2025 | 235 | 0.970 |
Why?
|
| Anti-Bacterial Agents | 16 | 2025 | 2596 | 0.940 |
Why?
|
| Spinal Puncture | 4 | 2020 | 52 | 0.930 |
Why?
|
| Hospitals, Pediatric | 11 | 2023 | 808 | 0.920 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 2 | 2022 | 18 | 0.860 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2020 | 2065 | 0.850 |
Why?
|
| Mass Screening | 7 | 2025 | 822 | 0.840 |
Why?
|
| Typhoid Fever | 1 | 2024 | 17 | 0.840 |
Why?
|
| Salmonella typhi | 1 | 2024 | 19 | 0.840 |
Why?
|
| Triage | 4 | 2016 | 144 | 0.840 |
Why?
|
| Paresis | 3 | 2018 | 32 | 0.820 |
Why?
|
| Medical Records | 1 | 2024 | 174 | 0.760 |
Why?
|
| Infection Control | 4 | 2011 | 158 | 0.760 |
Why?
|
| Health Personnel | 4 | 2023 | 541 | 0.760 |
Why?
|
| Reagent Kits, Diagnostic | 3 | 2008 | 52 | 0.750 |
Why?
|
| Drug Monitoring | 2 | 2019 | 292 | 0.750 |
Why?
|
| Rifamycins | 1 | 2022 | 18 | 0.740 |
Why?
|
| Risk Factors | 20 | 2025 | 11074 | 0.730 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2017 | 102 | 0.730 |
Why?
|
| Virus Diseases | 2 | 2023 | 285 | 0.720 |
Why?
|
| Hematologic Tests | 3 | 2019 | 36 | 0.710 |
Why?
|
| Emergency Medicine | 3 | 2020 | 172 | 0.700 |
Why?
|
| Problem Behavior | 1 | 2022 | 39 | 0.690 |
Why?
|
| Directly Observed Therapy | 5 | 2018 | 25 | 0.680 |
Why?
|
| Child Abuse, Sexual | 1 | 2022 | 68 | 0.670 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 2 | 2012 | 46 | 0.670 |
Why?
|
| Emigrants and Immigrants | 2 | 2014 | 169 | 0.660 |
Why?
|
| Foreign Bodies | 1 | 2022 | 98 | 0.650 |
Why?
|
| Periodicals as Topic | 1 | 2023 | 182 | 0.650 |
Why?
|
| Creatinine | 2 | 2019 | 398 | 0.650 |
Why?
|
| Case-Control Studies | 8 | 2025 | 3359 | 0.640 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2018 | 129 | 0.630 |
Why?
|
| Child Abuse | 3 | 2021 | 228 | 0.630 |
Why?
|
| Lymphadenitis | 4 | 2020 | 25 | 0.630 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2018 | 141 | 0.620 |
Why?
|
| Influenza A virus | 4 | 2019 | 145 | 0.620 |
Why?
|
| Pediatric Nursing | 1 | 2019 | 22 | 0.610 |
Why?
|
| Drug Administration Schedule | 5 | 2025 | 732 | 0.600 |
Why?
|
| Age Factors | 11 | 2021 | 2825 | 0.600 |
Why?
|
| Quality Improvement | 4 | 2016 | 722 | 0.600 |
Why?
|
| Tropical Medicine | 1 | 2020 | 103 | 0.590 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2019 | 11 | 0.590 |
Why?
|
| HIV Infections | 5 | 2019 | 2049 | 0.580 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 179 | 0.580 |
Why?
|
| Mycobacterium | 2 | 2010 | 30 | 0.580 |
Why?
|
| Kidney Function Tests | 1 | 2019 | 135 | 0.580 |
Why?
|
| Wounds, Nonpenetrating | 2 | 2020 | 218 | 0.570 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2016 | 400 | 0.560 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 298 | 0.560 |
Why?
|
| Time Management | 1 | 2018 | 8 | 0.560 |
Why?
|
| Disease Outbreaks | 3 | 2012 | 311 | 0.550 |
Why?
|
| Heart Transplantation | 1 | 2025 | 800 | 0.550 |
Why?
|
| Soft Tissue Infections | 4 | 2022 | 90 | 0.540 |
Why?
|
| Resuscitation | 3 | 2020 | 258 | 0.540 |
Why?
|
| Death | 1 | 2018 | 78 | 0.530 |
Why?
|
| Abdominal Pain | 3 | 2021 | 319 | 0.520 |
Why?
|
| Torso | 1 | 2017 | 13 | 0.520 |
Why?
|
| Physical Abuse | 1 | 2017 | 24 | 0.510 |
Why?
|
| Pelvic Bones | 1 | 2017 | 25 | 0.510 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2017 | 71 | 0.510 |
Why?
|
| Kidney Transplantation | 1 | 2022 | 558 | 0.500 |
Why?
|
| Emergency Treatment | 2 | 2023 | 78 | 0.500 |
Why?
|
| Standard of Care | 2 | 2023 | 133 | 0.500 |
Why?
|
| Length of Stay | 8 | 2019 | 1421 | 0.500 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2018 | 72 | 0.500 |
Why?
|
| Cough | 3 | 2020 | 97 | 0.500 |
Why?
|
| Shock | 2 | 2015 | 100 | 0.500 |
Why?
|
| Blood Proteins | 1 | 2017 | 143 | 0.500 |
Why?
|
| Patient Discharge | 2 | 2018 | 514 | 0.500 |
Why?
|
| Betacoronavirus | 1 | 2020 | 275 | 0.500 |
Why?
|
| Accidents, Traffic | 1 | 2017 | 102 | 0.490 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2016 | 22 | 0.490 |
Why?
|
| Contact Tracing | 2 | 2021 | 61 | 0.490 |
Why?
|
| Skull Fractures | 1 | 2016 | 46 | 0.480 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 195 | 0.480 |
Why?
|
| Pandemics | 6 | 2022 | 1118 | 0.480 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 159 | 0.480 |
Why?
|
| Leukocyte Count | 5 | 2020 | 246 | 0.470 |
Why?
|
| Accidental Falls | 1 | 2017 | 112 | 0.460 |
Why?
|
| Methotrexate | 1 | 2018 | 350 | 0.460 |
Why?
|
| Cerebrospinal Fluid | 5 | 2021 | 99 | 0.460 |
Why?
|
| Fractures, Bone | 2 | 2018 | 214 | 0.450 |
Why?
|
| Students | 2 | 2016 | 250 | 0.450 |
Why?
|
| Community-Acquired Infections | 3 | 2023 | 254 | 0.440 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2015 | 7 | 0.440 |
Why?
|
| Critical Illness | 2 | 2016 | 630 | 0.440 |
Why?
|
| Attitude of Health Personnel | 2 | 2024 | 707 | 0.440 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 351 | 0.440 |
Why?
|
| Decision Support Systems, Clinical | 3 | 2024 | 205 | 0.440 |
Why?
|
| Adolescent Behavior | 1 | 2016 | 166 | 0.430 |
Why?
|
| Health Education | 1 | 2016 | 228 | 0.430 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2015 | 57 | 0.430 |
Why?
|
| Colonic Diseases | 1 | 2015 | 38 | 0.430 |
Why?
|
| Whooping Cough | 2 | 2014 | 65 | 0.420 |
Why?
|
| Tuberculosis, Miliary | 1 | 2014 | 10 | 0.420 |
Why?
|
| Communicable Diseases | 1 | 2016 | 155 | 0.420 |
Why?
|
| United States | 16 | 2025 | 12072 | 0.420 |
Why?
|
| Intubation, Intratracheal | 1 | 2016 | 212 | 0.420 |
Why?
|
| Curriculum | 1 | 2019 | 798 | 0.410 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2015 | 117 | 0.410 |
Why?
|
| Odds Ratio | 5 | 2020 | 1211 | 0.410 |
Why?
|
| Leukocytosis | 3 | 2024 | 46 | 0.410 |
Why?
|
| Incidence | 9 | 2021 | 3360 | 0.400 |
Why?
|
| Diagnosis, Differential | 10 | 2020 | 1882 | 0.400 |
Why?
|
| Chromatography | 3 | 2008 | 29 | 0.400 |
Why?
|
| Clinical Competence | 3 | 2019 | 1050 | 0.400 |
Why?
|
| Escherichia coli Infections | 3 | 2021 | 198 | 0.390 |
Why?
|
| Sexually Transmitted Diseases | 3 | 2024 | 95 | 0.390 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2014 | 327 | 0.390 |
Why?
|
| Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2013 | 42 | 0.390 |
Why?
|
| Influenza B virus | 2 | 2016 | 102 | 0.380 |
Why?
|
| Prospective Studies | 14 | 2026 | 6459 | 0.380 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2024 | 157 | 0.370 |
Why?
|
| Mycobacterium fortuitum | 1 | 2012 | 1 | 0.370 |
Why?
|
| Cross-Cultural Comparison | 1 | 2012 | 58 | 0.370 |
Why?
|
| Foot Injuries | 1 | 2012 | 11 | 0.370 |
Why?
|
| Surge Capacity | 1 | 2012 | 8 | 0.370 |
Why?
|
| Tachycardia | 1 | 2012 | 66 | 0.360 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2022 | 333 | 0.360 |
Why?
|
| Cost of Illness | 1 | 2014 | 297 | 0.360 |
Why?
|
| Medication Adherence | 4 | 2018 | 338 | 0.360 |
Why?
|
| Wounds, Penetrating | 1 | 2012 | 140 | 0.350 |
Why?
|
| Time Factors | 8 | 2025 | 6196 | 0.350 |
Why?
|
| Bordetella Infections | 1 | 2011 | 2 | 0.350 |
Why?
|
| Drug Therapy | 1 | 2012 | 85 | 0.340 |
Why?
|
| Observer Variation | 2 | 2024 | 311 | 0.340 |
Why?
|
| Population Surveillance | 1 | 2014 | 396 | 0.340 |
Why?
|
| Diabetic Ketoacidosis | 2 | 2023 | 170 | 0.330 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 589 | 0.330 |
Why?
|
| Mycobacterium Infections | 2 | 2010 | 35 | 0.330 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 3 | 2022 | 235 | 0.330 |
Why?
|
| Shiga-Toxigenic Escherichia coli | 2 | 2021 | 6 | 0.330 |
Why?
|
| Hospitalization | 10 | 2023 | 1950 | 0.330 |
Why?
|
| Critical Care | 5 | 2020 | 686 | 0.320 |
Why?
|
| Mobile Health Units | 2 | 2012 | 24 | 0.320 |
Why?
|
| Young Adult | 11 | 2025 | 10103 | 0.320 |
Why?
|
| Predictive Value of Tests | 8 | 2021 | 2304 | 0.320 |
Why?
|
| Hemolytic-Uremic Syndrome | 2 | 2021 | 33 | 0.320 |
Why?
|
| Treatment Outcome | 11 | 2025 | 12936 | 0.310 |
Why?
|
| Monitoring, Physiologic | 1 | 2012 | 376 | 0.310 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2016 | 241 | 0.310 |
Why?
|
| Staphylococcal Scalded Skin Syndrome | 2 | 2021 | 8 | 0.310 |
Why?
|
| Physical Examination | 2 | 2022 | 171 | 0.310 |
Why?
|
| Polymerase Chain Reaction | 4 | 2019 | 1447 | 0.310 |
Why?
|
| Biomarkers | 7 | 2025 | 3385 | 0.300 |
Why?
|
| Tuberculosis, Meningeal | 2 | 2023 | 31 | 0.300 |
Why?
|
| Hospitals | 3 | 2025 | 435 | 0.290 |
Why?
|
| Cyclonic Storms | 2 | 2021 | 82 | 0.290 |
Why?
|
| Blood Culture | 2 | 2020 | 44 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 5 | 2023 | 1295 | 0.290 |
Why?
|
| Guidelines as Topic | 2 | 2020 | 198 | 0.280 |
Why?
|
| Prevalence | 5 | 2021 | 2701 | 0.280 |
Why?
|
| Surveys and Questionnaires | 6 | 2020 | 4066 | 0.280 |
Why?
|
| Multiple Organ Failure | 2 | 2020 | 145 | 0.280 |
Why?
|
| Interferon-gamma | 1 | 2010 | 544 | 0.280 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2011 | 262 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 981 | 0.280 |
Why?
|
| Staphylococcal Infections | 3 | 2022 | 571 | 0.280 |
Why?
|
| Acute Disease | 4 | 2024 | 1153 | 0.270 |
Why?
|
| Blood Cell Count | 2 | 2018 | 65 | 0.270 |
Why?
|
| Toxocariasis | 1 | 2008 | 29 | 0.270 |
Why?
|
| Guideline Adherence | 1 | 2011 | 387 | 0.270 |
Why?
|
| Risk Assessment | 4 | 2021 | 3711 | 0.270 |
Why?
|
| Cohort Studies | 8 | 2022 | 5063 | 0.270 |
Why?
|
| Chlamydia Infections | 2 | 2025 | 53 | 0.270 |
Why?
|
| Ascites | 1 | 2008 | 99 | 0.260 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 5196 | 0.260 |
Why?
|
| Cross Infection | 1 | 2011 | 339 | 0.260 |
Why?
|
| Pantoea | 1 | 2007 | 2 | 0.260 |
Why?
|
| Eosinophils | 1 | 2008 | 122 | 0.260 |
Why?
|
| Plant Diseases | 1 | 2007 | 21 | 0.260 |
Why?
|
| Renal Dialysis | 1 | 2014 | 951 | 0.260 |
Why?
|
| Body Temperature | 2 | 2021 | 126 | 0.260 |
Why?
|
| Delphi Technique | 4 | 2023 | 283 | 0.260 |
Why?
|
| Canada | 4 | 2021 | 327 | 0.250 |
Why?
|
| Anemia, Sickle Cell | 2 | 2025 | 334 | 0.250 |
Why?
|
| Lymphatic Diseases | 1 | 2007 | 28 | 0.250 |
Why?
|
| Tuberculosis, Central Nervous System | 1 | 2007 | 11 | 0.250 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2011 | 500 | 0.250 |
Why?
|
| Area Under Curve | 4 | 2023 | 304 | 0.240 |
Why?
|
| Reproducibility of Results | 7 | 2024 | 2904 | 0.240 |
Why?
|
| Algorithms | 4 | 2019 | 1680 | 0.240 |
Why?
|
| Delayed Diagnosis | 3 | 2023 | 131 | 0.240 |
Why?
|
| Staphylococcal Skin Infections | 2 | 2019 | 37 | 0.240 |
Why?
|
| Consensus | 5 | 2023 | 512 | 0.230 |
Why?
|
| Bacteria | 2 | 2020 | 521 | 0.230 |
Why?
|
| School Health Services | 2 | 2016 | 103 | 0.230 |
Why?
|
| Neck | 2 | 2017 | 140 | 0.230 |
Why?
|
| Gonorrhea | 1 | 2025 | 43 | 0.230 |
Why?
|
| Disease Progression | 4 | 2018 | 2200 | 0.230 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 1176 | 0.220 |
Why?
|
| Antigens, Viral | 1 | 2007 | 395 | 0.220 |
Why?
|
| Chi-Square Distribution | 2 | 2018 | 563 | 0.220 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2025 | 85 | 0.220 |
Why?
|
| Skin Tests | 2 | 2016 | 101 | 0.220 |
Why?
|
| Arthritis, Infectious | 1 | 2025 | 65 | 0.220 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 3061 | 0.210 |
Why?
|
| Sexual Health | 1 | 2024 | 19 | 0.210 |
Why?
|
| Referral and Consultation | 3 | 2019 | 564 | 0.210 |
Why?
|
| Multicenter Studies as Topic | 1 | 2025 | 294 | 0.210 |
Why?
|
| Contraception Behavior | 1 | 2024 | 30 | 0.210 |
Why?
|
| Preventive Health Services | 1 | 2024 | 59 | 0.210 |
Why?
|
| Orthopedic Surgeons | 1 | 2024 | 14 | 0.210 |
Why?
|
| Humeral Fractures | 1 | 2024 | 25 | 0.200 |
Why?
|
| Pregnancy in Adolescence | 1 | 2024 | 54 | 0.200 |
Why?
|
| Radiologists | 1 | 2024 | 53 | 0.200 |
Why?
|
| Health Surveys | 1 | 2024 | 261 | 0.200 |
Why?
|
| Headache | 2 | 2023 | 107 | 0.200 |
Why?
|
| Disease Management | 3 | 2017 | 558 | 0.190 |
Why?
|
| Emotions | 1 | 2026 | 350 | 0.190 |
Why?
|
| Brain Concussion | 1 | 2026 | 252 | 0.190 |
Why?
|
| Virus Cultivation | 3 | 2008 | 70 | 0.190 |
Why?
|
| Sex Factors | 2 | 2019 | 1356 | 0.190 |
Why?
|
| Child Health | 1 | 2023 | 72 | 0.180 |
Why?
|
| Circumcision, Male | 1 | 2022 | 22 | 0.180 |
Why?
|
| Hospitals, Public | 2 | 2019 | 48 | 0.180 |
Why?
|
| Craniocerebral Trauma | 1 | 2023 | 144 | 0.180 |
Why?
|
| Neoplasms | 2 | 2014 | 3016 | 0.180 |
Why?
|
| Chorioamnionitis | 1 | 2022 | 39 | 0.180 |
Why?
|
| Hospital Mortality | 2 | 2018 | 1064 | 0.180 |
Why?
|
| History, 20th Century | 1 | 2023 | 365 | 0.180 |
Why?
|
| Disaster Planning | 2 | 2014 | 68 | 0.170 |
Why?
|
| Mastitis | 1 | 2021 | 4 | 0.170 |
Why?
|
| Patient Acuity | 1 | 2021 | 66 | 0.170 |
Why?
|
| Antimicrobial Stewardship | 1 | 2023 | 89 | 0.170 |
Why?
|
| Tuberculoma, Intracranial | 2 | 2014 | 7 | 0.170 |
Why?
|
| Floods | 1 | 2021 | 21 | 0.170 |
Why?
|
| Reference Values | 2 | 2019 | 676 | 0.170 |
Why?
|
| ROC Curve | 2 | 2025 | 613 | 0.170 |
Why?
|
| Radiography | 3 | 2024 | 743 | 0.160 |
Why?
|
| Cause of Death | 1 | 2023 | 506 | 0.160 |
Why?
|
| Health | 1 | 2020 | 35 | 0.160 |
Why?
|
| Skin Diseases | 1 | 2022 | 143 | 0.160 |
Why?
|
| Developing Countries | 3 | 2019 | 305 | 0.160 |
Why?
|
| Musculoskeletal Pain | 1 | 2020 | 16 | 0.160 |
Why?
|
| Hospitals, Community | 1 | 2020 | 51 | 0.160 |
Why?
|
| Self Report | 1 | 2024 | 554 | 0.160 |
Why?
|
| Angioedema | 1 | 2020 | 21 | 0.160 |
Why?
|
| Erythrocyte Count | 1 | 2020 | 23 | 0.160 |
Why?
|
| Socioeconomic Factors | 2 | 2022 | 915 | 0.160 |
Why?
|
| Exanthema | 1 | 2021 | 74 | 0.160 |
Why?
|
| Trichomonas Infections | 1 | 2020 | 3 | 0.160 |
Why?
|
| Trichomonas vaginalis | 1 | 2020 | 10 | 0.160 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 215 | 0.160 |
Why?
|
| North America | 2 | 2021 | 255 | 0.160 |
Why?
|
| Otitis Media | 1 | 2020 | 88 | 0.160 |
Why?
|
| Nurses, Pediatric | 1 | 2019 | 2 | 0.160 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2022 | 177 | 0.150 |
Why?
|
| Epiglottitis | 1 | 2019 | 13 | 0.150 |
Why?
|
| Africa | 1 | 2020 | 135 | 0.150 |
Why?
|
| Medical History Taking | 1 | 2020 | 107 | 0.150 |
Why?
|
| Fluid Therapy | 3 | 2020 | 141 | 0.150 |
Why?
|
| Rehydration Solutions | 1 | 2009 | 8 | 0.150 |
Why?
|
| Earthquakes | 1 | 2019 | 5 | 0.150 |
Why?
|
| Tanzania | 1 | 2019 | 68 | 0.150 |
Why?
|
| Blepharoptosis | 1 | 2020 | 67 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2025 | 546 | 0.150 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2009 | 28 | 0.150 |
Why?
|
| Dehydration | 1 | 2009 | 40 | 0.150 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 223 | 0.150 |
Why?
|
| Hepatitis C | 1 | 2003 | 381 | 0.150 |
Why?
|
| Logistic Models | 3 | 2020 | 1797 | 0.150 |
Why?
|
| China | 1 | 2020 | 278 | 0.150 |
Why?
|
| Anxiety | 1 | 2026 | 1014 | 0.150 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 208 | 0.140 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 160 | 0.140 |
Why?
|
| Early Diagnosis | 1 | 2019 | 195 | 0.140 |
Why?
|
| Abdominal Injuries | 1 | 2020 | 123 | 0.140 |
Why?
|
| Africa South of the Sahara | 1 | 2018 | 121 | 0.140 |
Why?
|
| Research Design | 3 | 2026 | 716 | 0.140 |
Why?
|
| Central Nervous System Viral Diseases | 1 | 2018 | 13 | 0.140 |
Why?
|
| Streptococcal Infections | 2 | 2018 | 254 | 0.140 |
Why?
|
| Antidotes | 1 | 2018 | 10 | 0.140 |
Why?
|
| Diarrhea | 2 | 2020 | 301 | 0.140 |
Why?
|
| Blood Chemical Analysis | 1 | 2018 | 79 | 0.140 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 786 | 0.140 |
Why?
|
| Leucovorin | 1 | 2018 | 53 | 0.130 |
Why?
|
| Pneumonia, Bacterial | 2 | 2010 | 78 | 0.130 |
Why?
|
| Facial Injuries | 1 | 2018 | 23 | 0.130 |
Why?
|
| Ambulatory Care | 1 | 2021 | 401 | 0.130 |
Why?
|
| Patient Readmission | 2 | 2019 | 442 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2019 | 263 | 0.130 |
Why?
|
| Infliximab | 2 | 2016 | 61 | 0.130 |
Why?
|
| Airway Obstruction | 1 | 2019 | 173 | 0.130 |
Why?
|
| Syndrome | 1 | 2020 | 1155 | 0.130 |
Why?
|
| Appendectomy | 1 | 2018 | 88 | 0.130 |
Why?
|
| Meningitis, Viral | 1 | 2017 | 10 | 0.130 |
Why?
|
| Weight Gain | 1 | 2020 | 393 | 0.130 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2020 | 514 | 0.130 |
Why?
|
| Depression | 1 | 2026 | 1320 | 0.130 |
Why?
|
| Nose | 1 | 2018 | 115 | 0.130 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 15 | 0.130 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2016 | 23 | 0.130 |
Why?
|
| Neutrophils | 1 | 2019 | 371 | 0.130 |
Why?
|
| Erythrocytes | 1 | 2017 | 186 | 0.120 |
Why?
|
| Enterovirus | 1 | 2017 | 48 | 0.120 |
Why?
|
| Head Injuries, Closed | 1 | 2017 | 46 | 0.120 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 35 | 0.120 |
Why?
|
| Enterovirus Infections | 1 | 2017 | 48 | 0.120 |
Why?
|
| DNA, Viral | 1 | 2018 | 448 | 0.120 |
Why?
|
| Everolimus | 1 | 2016 | 50 | 0.120 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 89 | 0.120 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 171 | 0.120 |
Why?
|
| Injury Severity Score | 1 | 2017 | 235 | 0.120 |
Why?
|
| Regional Medical Programs | 1 | 2016 | 18 | 0.120 |
Why?
|
| Near Drowning | 1 | 2016 | 29 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2017 | 73 | 0.120 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 53 | 0.120 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2016 | 101 | 0.120 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1173 | 0.120 |
Why?
|
| Hemosiderosis | 1 | 2016 | 9 | 0.120 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 1319 | 0.120 |
Why?
|
| Urinalysis | 3 | 2022 | 72 | 0.120 |
Why?
|
| Jaundice | 1 | 2016 | 27 | 0.120 |
Why?
|
| Physicians | 1 | 2023 | 635 | 0.120 |
Why?
|
| Seizures | 1 | 2021 | 890 | 0.120 |
Why?
|
| Infant, Premature | 1 | 2021 | 872 | 0.120 |
Why?
|
| Drowning | 1 | 2016 | 48 | 0.110 |
Why?
|
| Failure to Thrive | 1 | 2016 | 86 | 0.110 |
Why?
|
| BCG Vaccine | 1 | 2016 | 105 | 0.110 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 209 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2019 | 1445 | 0.110 |
Why?
|
| Caregivers | 2 | 2012 | 598 | 0.110 |
Why?
|
| Lung | 2 | 2016 | 1535 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 889 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 339 | 0.110 |
Why?
|
| Spleen | 1 | 2016 | 258 | 0.110 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2015 | 79 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2018 | 407 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 345 | 0.110 |
Why?
|
| Program Evaluation | 1 | 2016 | 447 | 0.110 |
Why?
|
| Pediatric Obesity | 1 | 2020 | 419 | 0.110 |
Why?
|
| Botswana | 1 | 2014 | 76 | 0.110 |
Why?
|
| Pregnancy | 5 | 2024 | 7512 | 0.110 |
Why?
|
| Policy Making | 1 | 2014 | 63 | 0.100 |
Why?
|
| Comorbidity | 2 | 2021 | 1595 | 0.100 |
Why?
|
| Immunoassay | 2 | 2023 | 126 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 371 | 0.100 |
Why?
|
| Drug Costs | 1 | 2014 | 66 | 0.100 |
Why?
|
| Antivenins | 1 | 2014 | 13 | 0.100 |
Why?
|
| Snake Bites | 1 | 2014 | 17 | 0.100 |
Why?
|
| Liver Transplantation | 1 | 2023 | 1147 | 0.100 |
Why?
|
| Qualitative Research | 3 | 2024 | 730 | 0.100 |
Why?
|
| Professional Competence | 1 | 2014 | 97 | 0.100 |
Why?
|
| Health Policy | 1 | 2016 | 234 | 0.100 |
Why?
|
| Internet | 1 | 2016 | 420 | 0.100 |
Why?
|
| Glucose | 1 | 2018 | 853 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 645 | 0.100 |
Why?
|
| Allografts | 1 | 2014 | 220 | 0.100 |
Why?
|
| RNA | 1 | 2016 | 517 | 0.100 |
Why?
|
| Interviews as Topic | 3 | 2024 | 466 | 0.090 |
Why?
|
| Crohn Disease | 1 | 2016 | 292 | 0.090 |
Why?
|
| Hospital Charges | 1 | 2013 | 70 | 0.090 |
Why?
|
| Automation | 1 | 2012 | 65 | 0.090 |
Why?
|
| Anemia | 1 | 2016 | 354 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 789 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2016 | 398 | 0.090 |
Why?
|
| Office Visits | 1 | 2012 | 80 | 0.090 |
Why?
|
| Health Resources | 1 | 2013 | 131 | 0.090 |
Why?
|
| Psychotic Disorders | 1 | 2013 | 146 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 821 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 555 | 0.090 |
Why?
|
| Abscess | 2 | 2017 | 135 | 0.090 |
Why?
|
| Bordetella parapertussis | 1 | 2011 | 2 | 0.090 |
Why?
|
| Biopsy | 1 | 2015 | 1239 | 0.090 |
Why?
|
| Sodium Chloride | 1 | 2011 | 89 | 0.090 |
Why?
|
| Bordetella pertussis | 1 | 2011 | 15 | 0.090 |
Why?
|
| Community Health Services | 1 | 2012 | 86 | 0.090 |
Why?
|
| Albumins | 1 | 2011 | 87 | 0.080 |
Why?
|
| Professional-Family Relations | 1 | 2012 | 99 | 0.080 |
Why?
|
| Spain | 2 | 2021 | 56 | 0.080 |
Why?
|
| Adult | 7 | 2025 | 31282 | 0.080 |
Why?
|
| Hospitals, Urban | 1 | 2011 | 97 | 0.080 |
Why?
|
| Family Health | 1 | 2011 | 240 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1378 | 0.080 |
Why?
|
| Point-of-Care Systems | 1 | 2013 | 214 | 0.080 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2010 | 22 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2014 | 477 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2013 | 1483 | 0.080 |
Why?
|
| Primary Health Care | 1 | 2016 | 775 | 0.080 |
Why?
|
| Organ Dysfunction Scores | 2 | 2020 | 53 | 0.080 |
Why?
|
| Drug Resistance, Multiple | 1 | 2010 | 57 | 0.080 |
Why?
|
| Health Plan Implementation | 1 | 2009 | 39 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 972 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2014 | 499 | 0.070 |
Why?
|
| Heart Rate | 1 | 2012 | 577 | 0.070 |
Why?
|
| Inflammation | 1 | 2017 | 1489 | 0.070 |
Why?
|
| Blister | 1 | 2009 | 18 | 0.070 |
Why?
|
| Prognosis | 4 | 2021 | 4886 | 0.070 |
Why?
|
| Radiography, Thoracic | 1 | 2009 | 144 | 0.070 |
Why?
|
| Vasoconstrictor Agents | 2 | 2020 | 136 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 464 | 0.070 |
Why?
|
| Albendazole | 1 | 2008 | 26 | 0.070 |
Why?
|
| Toxocara | 1 | 2008 | 16 | 0.070 |
Why?
|
| C-Reactive Protein | 2 | 2023 | 450 | 0.070 |
Why?
|
| Anthelmintics | 1 | 2008 | 56 | 0.070 |
Why?
|
| Pseudomonas Infections | 1 | 2009 | 118 | 0.070 |
Why?
|
| Communication | 1 | 2012 | 543 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 387 | 0.070 |
Why?
|
| Immunologic Tests | 1 | 2007 | 18 | 0.060 |
Why?
|
| Neutropenia | 1 | 2009 | 209 | 0.060 |
Why?
|
| Influenza Vaccines | 1 | 2012 | 507 | 0.060 |
Why?
|
| Breast Feeding | 1 | 2008 | 240 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 1826 | 0.060 |
Why?
|
| Respiratory System | 1 | 2007 | 94 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 1545 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2012 | 807 | 0.060 |
Why?
|
| Electronic Health Records | 2 | 2024 | 844 | 0.060 |
Why?
|
| Guatemala | 2 | 2016 | 63 | 0.060 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2007 | 134 | 0.060 |
Why?
|
| False Negative Reactions | 1 | 2005 | 89 | 0.060 |
Why?
|
| Brain | 1 | 2018 | 3175 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 712 | 0.060 |
Why?
|
| Liver Abscess | 1 | 2005 | 13 | 0.060 |
Why?
|
| Hemodynamics | 2 | 2020 | 810 | 0.060 |
Why?
|
| Peru | 2 | 2016 | 54 | 0.060 |
Why?
|
| False Positive Reactions | 1 | 2005 | 143 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 1216 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2009 | 562 | 0.060 |
Why?
|
| Cross-Over Studies | 1 | 2025 | 258 | 0.050 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2018 | 229 | 0.050 |
Why?
|
| Contraception, Postcoital | 1 | 2024 | 4 | 0.050 |
Why?
|
| Pregnancy, Unplanned | 1 | 2024 | 9 | 0.050 |
Why?
|
| Contraception | 1 | 2024 | 61 | 0.050 |
Why?
|
| Glucocorticoids | 2 | 2016 | 348 | 0.050 |
Why?
|
| Herpesvirus 2, Human | 1 | 2022 | 16 | 0.050 |
Why?
|
| Reoviridae Infections | 1 | 2002 | 3 | 0.050 |
Why?
|
| Orthoreovirus, Mammalian | 1 | 2002 | 7 | 0.050 |
Why?
|
| Reproductive Health | 1 | 2023 | 48 | 0.050 |
Why?
|
| Cell Line | 1 | 2007 | 2552 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2023 | 230 | 0.050 |
Why?
|
| Dyspnea | 1 | 2023 | 159 | 0.040 |
Why?
|
| Sputum | 1 | 2022 | 113 | 0.040 |
Why?
|
| World War II | 1 | 2021 | 4 | 0.040 |
Why?
|
| Laboratories, Hospital | 1 | 2021 | 24 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2023 | 232 | 0.040 |
Why?
|
| Drainage | 2 | 2017 | 250 | 0.040 |
Why?
|
| Ferritins | 1 | 2021 | 104 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2002 | 337 | 0.040 |
Why?
|
| Chlamydia trachomatis | 1 | 2020 | 28 | 0.040 |
Why?
|
| Rape | 1 | 2020 | 21 | 0.040 |
Why?
|
| Infusions, Subcutaneous | 1 | 2009 | 7 | 0.040 |
Why?
|
| Tuberculosis Vaccines | 1 | 2019 | 14 | 0.040 |
Why?
|
| Philippines | 1 | 2019 | 22 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 144 | 0.040 |
Why?
|
| Eyelids | 1 | 2020 | 108 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2020 | 164 | 0.040 |
Why?
|
| Infusion Pumps | 1 | 2009 | 31 | 0.040 |
Why?
|
| Oxygen | 1 | 2023 | 548 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 1205 | 0.040 |
Why?
|
| Patient Admission | 1 | 2021 | 185 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2009 | 136 | 0.040 |
Why?
|
| Sex Offenses | 1 | 2020 | 52 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2020 | 149 | 0.040 |
Why?
|
| Blood Sedimentation | 1 | 2018 | 26 | 0.040 |
Why?
|
| Health Services Research | 1 | 2020 | 180 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 487 | 0.040 |
Why?
|
| Renal Replacement Therapy | 1 | 2020 | 172 | 0.030 |
Why?
|
| Contusions | 1 | 2018 | 16 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2021 | 361 | 0.030 |
Why?
|
| Streptococcus pyogenes | 1 | 2018 | 81 | 0.030 |
Why?
|
| Medical Audit | 1 | 2018 | 98 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2021 | 483 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 263 | 0.030 |
Why?
|
| Demography | 1 | 2018 | 237 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2020 | 266 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2019 | 247 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2016 | 32 | 0.030 |
Why?
|
| Swimming Pools | 1 | 2016 | 14 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 501 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2020 | 282 | 0.030 |
Why?
|
| Child Mortality | 1 | 2016 | 22 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2017 | 200 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2016 | 32 | 0.030 |
Why?
|
| General Practitioners | 1 | 2016 | 18 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2002 | 1692 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2016 | 125 | 0.030 |
Why?
|
| Nausea | 1 | 2016 | 83 | 0.030 |
Why?
|
| Urography | 1 | 2015 | 19 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2016 | 222 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 2016 | 94 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2015 | 56 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 67 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 423 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2016 | 270 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2016 | 700 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 351 | 0.030 |
Why?
|
| Vomiting | 1 | 2016 | 103 | 0.030 |
Why?
|
| Nursing Staff, Hospital | 1 | 2016 | 65 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2002 | 1559 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 335 | 0.030 |
Why?
|
| Fatigue | 1 | 2016 | 191 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2016 | 587 | 0.030 |
Why?
|
| Immunocompetence | 1 | 2014 | 31 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 978 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 429 | 0.030 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2014 | 50 | 0.030 |
Why?
|
| Animals | 3 | 2016 | 33912 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2017 | 385 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 1011 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2016 | 320 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2016 | 859 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2014 | 250 | 0.020 |
Why?
|
| Poverty | 1 | 2016 | 462 | 0.020 |
Why?
|
| Decision Making | 1 | 2018 | 726 | 0.020 |
Why?
|
| Emergency Responders | 1 | 2012 | 15 | 0.020 |
Why?
|
| Hydrocephalus | 1 | 2014 | 245 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2017 | 991 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 2012 | 88 | 0.020 |
Why?
|
| Disease Transmission, Infectious | 1 | 2012 | 71 | 0.020 |
Why?
|
| Reference Standards | 1 | 2012 | 231 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 276 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 2595 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 1246 | 0.020 |
Why?
|
| Ticarcillin | 1 | 2009 | 8 | 0.020 |
Why?
|
| Clavulanic Acid | 1 | 2009 | 7 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 3748 | 0.020 |
Why?
|
| Thigh | 1 | 2009 | 50 | 0.020 |
Why?
|
| Gentamicins | 1 | 2009 | 88 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2009 | 315 | 0.020 |
Why?
|
| Haemophilus parainfluenzae | 1 | 2005 | 11 | 0.010 |
Why?
|
| Haemophilus Infections | 1 | 2005 | 97 | 0.010 |
Why?
|
| Parents | 1 | 2012 | 1128 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2016 | 4686 | 0.010 |
Why?
|
| Mice | 2 | 2016 | 18301 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3763 | 0.010 |
Why?
|
| Cattle | 1 | 2002 | 501 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 2395 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 3464 | 0.010 |
Why?
|